ArticleNature medicine2024
Real-world implementation of a multilevel interventions program to prevent mother-to-child transmission of HBV in China.
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- [Chinese practice guidelines for the prevention and treatment of mother-to-child transmission of hepatitis B virus (version 2024)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Guideline
- Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China.Human vaccines & immunotherapeutics · 2025Trial
- Trends in clinical intervention practice for preventing mother-to-child transmission of hepatitis B virus in Guangdong Province, 2021-2023.Human vaccines & immunotherapeutics · 2026Article
- A Rare Pediatric Presentation: Concurrent Detection of All Five Hepatitis B Virus (HBV) Serological Markers.Journal of clinical medicine · 2026Article
- Transplacental Transfer of Telbivudine in Hepatitis B Virus-Infected Pregnant Women Treated with Telbivudine during the Third Trimester.ACS omega · 2026Article
- Over one-third of cancer cases and two-fifths of cancer deaths in southern China are preventable: Insights from the latest representative population-based cancer registry data and risk factor survey.International journal of cancer · 2026Article
- Characteristics of gut microbiota in pregnant hepatitis b virus carriers and their correlation with liver biochemical indicators.Frontiers in cellular and infection microbiology · 2026Article
- Using latent class analysis to characterize a high-misconception profile for targeted health education among HBsAg-positive pregnant women in China.Frontiers in public health · 2026Article
- Clinical, pathological characteristics and long-term outcomes of hepatitis B virus related cirrhosis in pediatric observational study.World journal of gastroenterology · 2025Observational
- Effectiveness of the National Immunisation Programme and the catch-up vaccination on the incidence of hepatitis B in China: an interrupted time series analysis from 2005 to 2019.BMJ global health · 2025Article
- Mother-to-child transmission of hepatitis B virus, its associated risk factors, and the adoption of maternal antiviral therapy in eastern China: a retrospective cohort study.BMC infectious diseases · 2025Article
- Hepatitis B Virus e Antigen in Mother-to-Child Transmission and Clinical Management of Hepatitis B.Viruses · 2025Review
- Optimizing the prevention of mother-to-child transmission of hepatitis B through integrated care models: a pilot study in Jiangsu Province, China.BMC public health · 2025Article
- Global burden of liver cirrhosis: trends from 1990-2021 and projections to 2060.Journal of health, population, and nutrition · 2025Article
- Global strategies and actions to eliminate hepatitis B virus infection.Clinical and molecular hepatology · 2025Review
- Epidemiology, Achievements, and Challenges in the Elimination of Hepatitis B in China.Journal of clinical and translational hepatology · 2025Review
- Evaluations of Community-based Healthcare Management for Patients with Chronic Viral Hepatitis - Shanghai Municipality, China, 2012-2023.China CDC weekly · 2025Article
- Level of antibody to hepatitis B surface antigen declined below 10 mIU/ml is still protective.NPJ vaccines · 2025Article
- Delivering integrated and standardized services to eliminate mother-to-child transmission of sexually transmitted infections: experience of the E-Clinic model in a Chinese pilot district.Health policy and planning · 2025Article
- PGLYRP2 drives hepatocyte-intrinsic innate immunity by trapping and clearing hepatitis B virus.The Journal of clinical investigation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 16 institutions in 3 countries.
Funding
Abstract
Reducing hepatitis B virus (HBV) mother-to-child transmission (MTCT) is a fundamental step toward the HBV elimination goal. The multicentred, multilevel SHIELD program aimed to use an intense intervention package to reduce HBV MTCT in China. This study was conducted in diverse health settings across China, encompassing 30,109 pregnant women from 178 hospitals, part of the interim analysis of stage II of the SHIELD program, and 8,642 pregnant women from 160 community-level health facilities in stage III of the SHIELD program. The study found that the overall MTCT rate was 0.23% (39 of 16,908; 95% confidence interval (CI): 0.16-0.32%) in stage II and 0.23% (12 of 5,290; 95% CI: 0.12-0.40%) in stage III. The MTCT rate was lower among participants who were compliant with the interventions (stage II: 0.16% (95% CI: 0.10-0.26%); stage III: 0.03% (95% CI: 0.00-0.19%)) than among those who were noncompliant (3.16% (95% CI: 1.94-4.85%); 1.91% (95% CI: 0.83-3.73%); P < 0.001). Our findings demonstrate that the comprehensive interventions among HBV-infected pregnant women were feasible and effective in dramatically reducing MTCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.